Beta-Site APP-Cleaving Enzyme 2 (CT) Blocking Peptide

Beta-Site APP-Cleaving Enzyme 2 (CT) Blocking Peptide

Product No.: B366

[product_table name="All Top" skus="B366"]

- -
- -
Target
Beta-Site Amyloid Precursor Protein Cleaving Enzyme 2
Product Type
Blocking Peptide
Alternate Names
BACE2, Asp2, DRAP

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Product Concentration
0.2 mg/ml
Amino Acid Location
This peptide sequence is located at amino acids 496 to 511 of Human BACE2 protein.
Formulation
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Amino Acid Sequence
16 amino acids near the carboxy terminus of human BACE2.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Background
Beta-Site APP-Cleaving Enzyme 2 peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

Antigen Details

References & Citations

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21 2. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC . Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4 3. Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 1999;96:1457-62 (WD0600)
Products are for research use only. Not for use in diagnostic or therapeutic procedures.